<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801931</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC3457</org_study_id>
    <secondary_id>CHNY-06-533</secondary_id>
    <nct_id>NCT00801931</nct_id>
  </id_info>
  <brief_title>Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders</brief_title>
  <official_title>Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and toxicity and feasibility of double
      umbilical cord blood transplantation (DUCBT) in patients with selected malignant and
      non-malignant, and to quantify the percentage and donor sources of mixed donor chimerism
      following DUCBT in patients with selected malignant and non-malignant disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic stem cell transplantation from an human leukocyte antigen (HLA) matched related
      family donor is the treatment of choice for a wide variety of malignant and non-malignant
      disorders. Unfortunately, only 25% of potential recipients have an HLA matched related family
      donor, leaving approximately 75% of potential recipients requiring alternative sources of HLA
      matched allogeneic stem cells. One potential source of HLA matched allogeneic stem cells is
      from unrelated adult donors that have been identified in the national and international donor
      registries. However, several limitations restrict the uniform utilization of unrelated
      allogeneic adult donors including ethnic background of the recipient, acuity and timing of
      planned allogeneic transplant, availability of donor, and high risk of severe acute
      graft-versus-host disease (GVHD) (III/IV), among others. The investigators have recently
      identified a new alternative source of allogeneic stem cells, unrelated cryopreserved
      placental/cord blood stem cells.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date type="Actual">September 6, 2007</start_date>
  <completion_date type="Actual">May 5, 2009</completion_date>
  <primary_completion_date type="Actual">May 5, 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Failure Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of patients to experience graft failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate (Complete and Partial Response)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response rate to each regimen will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS will be summarized using the Kaplan and Meier curves.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DFS will be summarized using the Kaplan and Meier curves.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Neuroblastoma</condition>
  <condition>Immunodeficiencies</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>A: Full Intensity with TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start their pre-conditioning regimen on Day -8. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1.The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/mycophenolate mofetil (MMF).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Full intensity without TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. Granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Moderate Intensity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Reduced Intensity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E: Fanconi's Anemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and horse antithymocyte globulin on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F: Regimen for non-malignant diseases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.</description>
    <arm_group_label>C: Moderate Intensity</arm_group_label>
    <other_name>Lemtrada</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <arm_group_label>A: Full Intensity with TBI</arm_group_label>
    <arm_group_label>E: Fanconi's Anemia</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 45mg/m2 (1.5 mg/kg IV for children &lt;1 year of age or &lt;10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.</description>
    <arm_group_label>B: Full intensity without TBI</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration &gt;0.5 mg/mL), through a central venous access device over 2 hours.</description>
    <arm_group_label>B: Full intensity without TBI</arm_group_label>
    <arm_group_label>C: Moderate Intensity</arm_group_label>
    <arm_group_label>D: Reduced Intensity</arm_group_label>
    <arm_group_label>F: Regimen for non-malignant diseases</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenytoin</intervention_name>
    <description>Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.</description>
    <arm_group_label>F: Regimen for non-malignant diseases</arm_group_label>
    <other_name>Fosphenytoin</other_name>
    <other_name>Dilantin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.</description>
    <arm_group_label>C: Moderate Intensity</arm_group_label>
    <arm_group_label>D: Reduced Intensity</arm_group_label>
    <arm_group_label>E: Fanconi's Anemia</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.</description>
    <arm_group_label>A: Full Intensity with TBI</arm_group_label>
    <arm_group_label>E: Fanconi's Anemia</arm_group_label>
    <arm_group_label>F: Regimen for non-malignant diseases</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Horse Antithymocyte Globulin</intervention_name>
    <description>Horse Antithymocyte Globulin (ATG [horse]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.</description>
    <arm_group_label>E: Fanconi's Anemia</arm_group_label>
    <other_name>Atgam</other_name>
    <other_name>ATG[horse]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit Antithymocyte Globulin</intervention_name>
    <description>Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.</description>
    <arm_group_label>A: Full Intensity with TBI</arm_group_label>
    <arm_group_label>B: Full intensity without TBI</arm_group_label>
    <arm_group_label>D: Reduced Intensity</arm_group_label>
    <arm_group_label>F: Regimen for non-malignant diseases</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).</description>
    <arm_group_label>A: Full Intensity with TBI</arm_group_label>
    <other_name>Tepadina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be eligible for double cord blood stem cell transplant (TNC ≥ 4x107/kg
             of two combined units) if available single cord blood has TNC ≤4.0 x 107/kg and they
             lack a matched (5-6/6) family donor, a 10/10 unrelated adult donor, and/or if their
             disease status required emergent stem cell transplant and they could not wait 2-3
             months for searching for a matched unrelated adult donor.

          -  Adequate renal function defined as:Serum creatinine &lt;1.5 x normal, or Creatinine
             clearance or radioisotope glomerular filtration rate (GFR) &gt;60 ml/min/m2 or &gt;60
             ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range.

          -  Adequate liver function defined as:Total bilirubin &lt;1.5 x normal, or serum
             glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase (AST)) or serum
             glutamic pyruvic transaminase (SGPT) (alanine aminotransferase (ALT)) &lt;3.0 x normal

          -  Adequate cardiac function defined as:Shortening fraction &gt;27% by echocardiogram, or
             Ejection fraction &gt;47% by radionucleotide angiogram or echocardiogram.

          -  Adequate pulmonary function defined as:Uncorrected diffusing capacity of the lungs for
             carbon monoxide (DLCO) 50% by pulmonary function test.For children who are
             uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse
             oximetry &gt;94% on room air.

        Eligibility for Moderate Intensity, Reduced Intensity Regimen and Fanconi's Anemia
        (Regimens C, D and E)

          -  Adequate renal function defined as: Serum creatinine &lt;2.0 x normal, or Creatinine
             clearance or radioisotope GFR 40 ml/min/m2 or &gt;40 ml/min/1.73 m2 or an equivalent GFR
             as determined by the institutional normal range.

          -  Adequate liver function defined as:Total bilirubin &lt;2.5 x normal, or SGOT (AST) or
             SGPT (ALT) &lt;5.0 x normal

          -  Adequate cardiac function defined as:Shortening fraction of &gt;25% by echocardiogram, or
             Ejection fraction &gt;40% by radionucleotide angiogram or echocardiogram.

          -  Adequate pulmonary function defined as:Uncorrected DLCO &gt;35% by pulmonary function
             test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise
             intolerance, and a pulse oximetry &gt;94% on room air.

        Exclusion Criteria:

          -  Females who are pregnant or breast-feeding

          -  Patients with documented uncontrolled infection at the time of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash Satwani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia Presbyterian Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <results_first_submitted>July 25, 2017</results_first_submitted>
  <results_first_submitted_qc>March 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2019</results_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Prakash Satwani</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics at the Columbia University Med, Department of Pediatrics BMT</investigator_title>
  </responsible_party>
  <keyword>Cord Blood Transplant</keyword>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
    <mesh_term>Fosphenytoin</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was only 1 subjected enrolled. The 1 subject was enrolled into Arm - Experimental: C: Moderate Intensity.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental: C: Moderate Intensity</title>
          <description>Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There was only 1 subjected enrolled. The 1 subject was enrolled into Arm - Experimental: C: Moderate Intensity.</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental: C: Moderate Intensity</title>
          <description>Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Graft Failure Rate</title>
        <description>Number of patients to experience graft failure.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Not enough subjects were enrolled for data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Includes all subjects in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Failure Rate</title>
          <description>Number of patients to experience graft failure.</description>
          <population>Not enough subjects were enrolled for data analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (Complete and Partial Response)</title>
        <description>Response rate to each regimen will be measured.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Not enough subjects were enrolled for data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Includes all subjects in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Complete and Partial Response)</title>
          <description>Response rate to each regimen will be measured.</description>
          <population>Not enough subjects were enrolled for data analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS will be summarized using the Kaplan and Meier curves.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Not enough subjects were enrolled for data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Includes all subjects in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS will be summarized using the Kaplan and Meier curves.</description>
          <population>Not enough subjects were enrolled for data analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS)</title>
        <description>DFS will be summarized using the Kaplan and Meier curves.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Not enough subjects were enrolled for data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Includes all subjects in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS)</title>
          <description>DFS will be summarized using the Kaplan and Meier curves.</description>
          <population>Not enough subjects were enrolled for data analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental: C: Moderate Intensity</title>
          <description>Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure with Cardiac Tamponade</sub_title>
                <description>Led to death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was only 1 subjected enrolled. The 1 subject was enrolled into Arm - Experimental: C: Moderate Intensity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prakash Satwani, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-0223</phone>
      <email>ps2087@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

